Mechanism of Action
Phosphate and Vitamin D Regulation
FGF-23 binds to FGFR1/3/4 in complex with the co-receptor alpha-Klotho, which is highly expressed in renal tubules and parathyroid glands. In the kidney, FGF-23 suppresses expression of sodium-phosphate cotransporters (NaPi-IIa, NaPi-IIc) in proximal tubules, reducing phosphate reabsorption. Simultaneously, FGF-23 inhibits 1-alpha-hydroxylase (CYP27B1) and stimulates 24-hydroxylase (CYP24A1), resulting in lower calcitriol levels and downstream calcium absorption reduction.
Parathyroid and Bone Interactions
FGF-23 suppresses PTH secretion from parathyroid glands in a Klotho-dependent manner, creating a feedback axis with PTH. In bone, FGF-23 production is stimulated by phosphate intake, calcitriol, and PTH. PHEX (phosphate-regulating endopeptidase) and DMP1 (dentin matrix protein 1) mutations that cause XLH and ARHR do so by preventing FGF-23 cleavage, leading to excess intact FGF-23 and pathological phosphate wasting.
Cardiac and Inflammatory Effects
In CKD, elevated FGF-23 (often >100-fold above normal) activates FGFR4 in cardiac myocytes in a Klotho-independent manner, triggering calcineurin/NFAT signaling and pathological left ventricular hypertrophy. FGF-23 also promotes endothelial dysfunction, increases oxidative stress, and impairs neutrophil function. These off-target effects explain why high FGF-23 predicts cardiovascular events independent of phosphate or PTH levels.
Research Summary
X-Linked Hypophosphatemia (XLH)
FDA Approved (indirect)Burosumab, which neutralizes FGF-23, is FDA-approved for XLH and TIO. Clinical trials showed normalization of serum phosphate, healing of rickets lesions, improved skeletal mineralization, and better growth in children. In adults, burosumab improved fracture healing and reduced pseudofracture burden. This validates FGF-23 as the central pathological driver in XLH.
Chronic Kidney Disease
Active ResearchFGF-23 is an early biomarker of CKD mineral bone disorder, rising before phosphate or PTH become abnormal. Clinical studies show FGF-23 >200 RU/mL is independently associated with 3-4x higher cardiovascular mortality. Interventions targeting FGF-23 reduction (dietary phosphate restriction, phosphate binders, SGLT2 inhibitors) are being investigated. Direct anti-FGF-23 therapy in CKD is under study with mixed results.
Aging and Klotho
EmergingKlotho (FGF-23 co-receptor) decline is a feature of aging and associates with sarcopenia, cognitive decline, and vascular aging. As Klotho decreases, FGF-23 signaling becomes dysregulated. Soluble Klotho administration in animal models reverses FGF-23-mediated cardiac hypertrophy. The FGF-23/Klotho axis is increasingly viewed as a longevity pathway target.
Calculate your FGF-23 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| FGF-23 measurement | Blood draw (biomarker) | Fasting morning sample | Serum or plasma (ELISA) |
| Recombinant FGF-23 (animal) | 50-200 mcg/kg SC | Daily x 5-7 days | SC injection |
| Anti-FGF-23 (burosumab model) | 1 mg/kg SC | Every 4 weeks | SC (clinical reference) |
FGF-23 is primarily a biomarker and therapeutic target rather than an administered research peptide.
Interactions
Safety Profile
Recombinant FGF-23 administration causes dose-dependent hypophosphatemia, hypocalcemia risk, and reduced vitamin D. These are the expected on-target effects. At supraphysiological doses, cardiac effects via FGFR4 are a concern. As a biomarker, elevated endogenous FGF-23 is a risk factor rather than a treatment. Burosumab (anti-FGF-23) risks include injection site reactions and hyperphosphatemia if dosed too aggressively.
References
- [1]Shimada T, et al. FGF-23 is a counter-regulatory phosphaturic hormone of vitamin D metabolism. Proc Natl Acad Sci. 2004.
- [2]Isakova T, et al. FGF-23 and mortality among CKD patients. JAMA. 2011;305:2432-2439.
- [3]Insogna KL, et al. Burosumab therapy in adults with XLH. NEJM. 2018;379:1417-1427.